STOCK TITAN

Cibus, Inc. - CBUS STOCK NEWS

Welcome to our dedicated page for Cibus news (Ticker: CBUS), a resource for investors and traders seeking the latest updates and insights on Cibus stock.

Cibus, Inc. (Nasdaq: CBUS) is a pioneering biotechnology company that focuses on developing and commercializing proprietary gene-editing technologies. At the heart of Cibus’ innovation is its Rapid Trait Development System (RTDS®), a cutting-edge gene-editing platform that integrates crop-specific cell biology with advanced gene-editing techniques. The company's mission is to enhance plant traits to address crucial farming challenges related to productivity, disease resistance, and environmental sustainability.

One of Cibus’ key projects includes the development of herbicide tolerance traits in rice. The recent field trials for the HT1 and HT3 traits have shown promising results, meeting or exceeding performance expectations. This success has led to the first transfer of customer seeds containing these traits, marking a significant step in the company's commercial journey.

In addition, Cibus has made notable progress with its Pod Shatter Reduction (PSR) trait in canola. The PSR trait aims to minimize yield losses due to pod shattering, a common issue in canola farming. The successful field trials have enabled the transfer of PSR traits to multiple seed developers, with commercial hybrid sales expected as early as 2025.

Cibus is also at the forefront of legislative changes in Europe, supporting new regulations for New Genomic Techniques (NGTs) that classify certain gene-editing methods as ‘Conventional-like’. This regulatory recognition is expected to facilitate the commercial adoption of Cibus’ gene-edited traits across the European Union.

Recently, Cibus announced a strategic partnership with Loveland Products Inc. to commercialize herbicide tolerance traits in rice for the southern US market. This collaboration underscores Cibus’ commitment to providing innovative solutions to pressing agricultural challenges.

Cibus’ proprietary Trait Machine™ System is integral to its technology breakthrough. This system standardizes the gene-editing process, allowing precise modifications in a seed company’s elite germplasm without using foreign DNA or transgenes. The Trait Machine is currently operational for canola and rice, with broader applications anticipated in the future.

Overall, Cibus is revolutionizing plant breeding with its high-throughput gene-editing technology, addressing critical agricultural challenges, and paving the way for more sustainable and productive farming practices globally.

Rhea-AI Summary

Cibus, an agricultural technology company listed on Nasdaq (CBUS), announced its participation in two upcoming investor events in June 2024. Rory Riggs, Co-Founder, CEO, and Chairman, will present at the Stifel Cross Sector Insight Conference in Boston, MA on June 5 at 1:50 p.m. ET. Additionally, both Riggs and Co-Founder, President, and COO Peter Beetham will present at the Bank of America AgTech Conference virtually on June 6 at 3:00 p.m. ET. These events will provide Cibus with the opportunity to connect with investors and discuss its business developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
conferences
-
Rhea-AI Summary

Cibus has achieved a major milestone by successfully editing Canola with a third mode of action to resist White Mold (Sclerotinia). This advancement is expected to enhance disease resistance in Canola and potentially other crops like Soybean and various produce. The edited Canola plants will undergo controlled environment testing later this year. Cibus aims to improve crop yields and reduce fungicide use, thereby lowering input costs. This development underscores the company's capability in accelerating the creation of complex gene-edited traits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
Rhea-AI Summary

Cibus (Nasdaq: CBUS), a leader in agricultural biotechnology, commends the Canadian Food Inspection Agency (CFIA) for updating its feed guidelines to regulate plants developed using gene editing, similar to conventional breeding. The guideline revision is part of a global trend, including the UK and EU, recognizing gene editing technologies like Cibus' RTDS® as safe and equivalent to traditional breeding methods. Cibus' RTDS platform aims to enhance global food productivity and sustainability. These guidelines are important for innovation and investment in Canada's agri-food sector, particularly for crops like canola. Cibus is progressing towards commercializing its Pod Shatter Reduction trait in canola, promising yield protection for Canadian farmers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
Rhea-AI Summary

Cibus, Inc. (Nasdaq: CBUS) will participate in the BMO Global Farm to Market Conference with a presentation hosted by the CEO and COO on May 16, 2024. The company utilizes gene editing technologies to enhance plant traits in seeds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
conferences
-
Rhea-AI Summary

Cibus, Inc. (Nasdaq: CBUS) reported Q1 2024 financial results and business update. Key highlights include success in single cell regeneration platform for Wheat, agreements in Rice, advancing Pod Shatter Reduction trait in Canola, and recognition by Fast Company. The PR also mentions global approval momentum for new genomic techniques, regulatory shifts in EU, and appointment of a new Chief Legal Officer, Jason Stokes. Financially, the company reported a cash position of $24.5 million, increased R&D and SG&A expenses, and a net loss of $27.0 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
-
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) will report its first quarter 2024 financial results on May 9, 2024. The company, a leader in agricultural biotechnology using gene editing technologies for plant traits, will host a conference call to discuss the results and company updates. Participants can join the call or access a replay via phone or online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences earnings
Rhea-AI Summary
Cibus, Inc. (CBUS) achieved significant milestones in 2023, including successful transfers of gene-edited elite germplasm for commercialization, collaboration agreements with major seed companies, positive greenhouse and field trial results, and opening a gene editing production facility. The company also reported a positive vote in the EU Parliament for new genomic techniques, a breakthrough in regenerating Wheat plants, and raised $20.3 million via a direct offering. The CEO highlighted the progress in commercializing developed traits, advancements in Sclerotinia resistance, and the industry's shift towards gene editing technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.1%
Tags
-
Rhea-AI Summary
Cibus, Inc. (Nasdaq: CBUS) has been recognized as the 2nd most innovative company in the agriculture category on Fast Company's list of the World's Most Innovative Companies of 2024. The company uses gene editing technologies to develop plant traits, aiming to transform the agricultural industry. Cibus has achieved significant milestones, including merging with Calyxt, opening a cutting-edge facility, and successfully commercializing traits like Pod Shatter Reduction in Canola and herbicide tolerance traits in Rice. The company's proprietary gene editing platform, RTDS, is driving its vision of creating sustainable food solutions and reducing chemical use in agriculture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
none
-
Rhea-AI Summary
Cibus, Inc. (CBUS) announced participation in the 36th Annual Roth Conference to discuss gene editing in agriculture and the implications of a post-GMO era.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
conferences
Rhea-AI Summary
Cibus, Inc. (CBUS) will report its fourth quarter 2023 financial results on March 21, 2024. The management team will host a conference call and webcast to discuss the results and company updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences earnings

FAQ

What is the current stock price of Cibus (CBUS)?

The current stock price of Cibus (CBUS) is $2.645 as of December 20, 2024.

What is the market cap of Cibus (CBUS)?

The market cap of Cibus (CBUS) is approximately 73.8M.

What is the main focus of Cibus, Inc.?

Cibus, Inc. focuses on developing and commercializing gene-editing technologies to enhance plant traits, addressing productivity, disease resistance, and sustainability issues in farming.

What is the Rapid Trait Development System (RTDS®)?

RTDS® is Cibus’ proprietary gene-editing platform that integrates crop-specific cell biology with advanced gene-editing technologies to develop precise plant traits without using foreign DNA or transgenes.

What recent achievements has Cibus made in rice farming?

Cibus has successfully developed herbicide tolerance (HT1 and HT3) traits for rice, which have met or exceeded performance expectations in field trials and are now being transferred to seed developers for commercial use.

How is Cibus addressing the issue of pod shatter in canola?

Cibus has developed a Pod Shatter Reduction (PSR) trait for canola, which has shown positive field trial results and is being transferred to multiple seed developers, with commercial hybrid sales expected by 2025.

What recent legislative changes in Europe support Cibus’ technology?

The European Parliament recently voted in favor of new regulations for New Genomic Techniques (NGTs), classifying certain gene-editing methods as ‘Conventional-like’, facilitating the adoption of Cibus’ traits in the EU.

What is the Trait Machine™ System?

The Trait Machine™ System is Cibus’ standardized end-to-end gene-editing process that allows precise modifications in a seed company’s elite germplasm, ensuring the development of high-quality plant traits.

What is the significance of Cibus’ partnership with Loveland Products Inc.?

Cibus has partnered with Loveland Products to commercialize herbicide tolerance traits in rice, focusing on the southern US market to address weed management challenges.

How does Cibus plan to address Sclerotinia resistance in crops?

Cibus is developing multiple modes of action for Sclerotinia (White Mold) resistance in canola and other crops, with the goal of providing durable resistance and reducing crop losses.

Does Cibus use genetically modified organisms (GMOs) in its technology?

No, Cibus’ gene-editing technology does not use foreign DNA or transgenes, making its developed traits indistinguishable from those produced by conventional breeding.

What crops does Cibus focus on for its gene-editing technology?

Cibus focuses on major global row crops with large acreage such as canola, corn, rice, soybean, and wheat.

Cibus, Inc.

Nasdaq:CBUS

CBUS Rankings

CBUS Stock Data

73.81M
23.15M
24.24%
33.73%
7.39%
Biotechnology
Agricultural Chemicals
Link
United States of America
SAN DIEGO